International
The Morning Science

What science found today

‹
 

Research

Tirzepatide moves more than half of treated teens below obesity threshold, new clinical trial reports

Medical Xpress ·

Tirzepatide moves more than half of treated teens below obesity threshold, new clinical trial reports

The Brief

  • Tirzepatide (Zepbound), a once-weekly injectable, acts on two gut hormone targets, GIP and GLP-1.
  • A new clinical trial reports that more than half of treated teens moved below the obesity threshold.

Why it matters

The trial suggests a dual-action drug can shift obesity status in adolescents, which is relevant to how pediatric obesity treatment is studied and managed.

Who’s affected

  • clinicians and researchers in pediatric obesity
  • families of teenagers with obesity

Tirzepatide (Zepbound) is a once-weekly injectable medication that hits two targets at once. This dual-action drug mimics the effects of two natural gut hormones in the body—glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Working together…

How do you feel about this?

0 Comments

    Tirzepatide moves more than half of treated teens below obesity threshold, new clinical trial reports – The Morning Science